| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost...
																	BioNTech (NASDAQ:BNTX) raises FY2025 sales outlook from $1.787 billion-$2.314 billion to $3.040 billion-$3.274 billion.
																	BioNTech (NASDAQ:BNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $0.75 by 1...
																	
																	
																	https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...
																	JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:BNTX) with a Neutral and lowers the price target from $121 to $120.
																	Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherap...